Physician profile

Bryan T Pierce

Family Medicine · Wichita, KS

NPI 1700379286

$805.38

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$105.14

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $322.21 2019-2023
Novo Nordisk INC $192.62 2021-2023 Ozempic, Rybelsus
Janssen Pharmaceuticals, INC $75.79 2021
Amgen INC. $52.31 2022
Abbott Laboratories $43.18 2022
Astrazeneca Pharmaceuticals LP $30.30 2022
Bayer Healthcare Pharmaceuticals INC. $16.72 2022
Amarin Pharma, INC. $16.04 2021
Eisai INC. $14.96 2022
Pfizer INC. $14.56 2023
Xeris Pharmaceuticals, INC. $14.55 2022
Kowa Pharmaceuticals America, INC. $12.14 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bryan T Pierce

$805.38

in general payments reported 2019-2025

Years
2019-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/5454701/bryan-t-pierce

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.